Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti

Safety Profile:
Gilead and Arcellx's CAR-T therapy, anito-cel, has shown no cases of delayed neurotoxicities such as Guillain-Barré syndrome, Parkinson’s-like symptoms, or cranial nerve palsies in early trials.

Efficacy:
Preliminary findings from the Phase II iMMagine-1 trial demonstrated a 95% overall response rate and a 62% complete response or stringent complete response rate in patients with relapsed or refractory multiple myeloma.

Phase 3 Progress:
The first patient has been dosed in the Phase 3 iMMagine-3 study, further advancing the development of anito-cel.

Competitive Advantage:
Analysts suggest that anito-cel’s safety profile could differentiate it from Legend Biotech and J&J’s Carvykti, potentially making it a more appealing therapeutic option.

ASH 2024 Presentation:
Gilead and Arcellx will present these findings at the 2024 Annual Meeting of the American Society of Hematology (ASH 2024), highlighting the potential of anito-cel as a best-in-class CAR-T therapy for multiple myeloma.